Takeda (TAK) · Pharmaceuticals
Takeda Q1 FY2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Takeda is lining up a run of late-stage launches, led by an orexin agonist for narcolepsy type 1 and rusfertide, to offset generic erosion of VYVANSE.
Takeda is moving from defending older products to launching new ones. It is on track to bring the first and only orexin agonist to patients with narcolepsy type 1 (NT1). Rusfertide has U.S. FDA priority review, with a U.S. launch expected in the second half of 2026. Management says demand growth continues for its leading inflammatory bowel disease (IBD) brand, even though its sales dipped at constant exchange rates. VYVANSE generic erosion in the U.S. is the main drag.
Management is steering toward a pipeline-led portfolio, with another U.S. launch planned for the first half of 2027. It is also building plasma capacity abroad, starting with a collaboration with the Indonesian government. The tension is timing: new launches must grow fast enough to cover lost sales from generics. Takeda also carries heavy restructuring spending and the AMITIZA antitrust litigation, which it expects to run roughly 3 to 5 years.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.
Key numbers
- Revenue (JPY billion) · GAAP
- 1.2T
- Operating profit (JPY billion) · GAAP
- 201.4B
- Operating margin · GAAP
- 16.5%
- Net profit attributable to owners (JPY billion) · GAAP
- 113.2B
- Basic EPS (JPY) · GAAP
- 71.65
- Gross margin · GAAP
- 66.7%
- Core EPS (JPY) · non-GAAP
- 154
- Core operating profit (JPY billion) · non-GAAP
- 358.9B
up 10.2% from a year ago at actual exchange rates, (0.5)% at constant exchange rates
up 9.1% from a year ago at actual exchange rates, (3.1)% at constant exchange rates
down 0.2 pp from 16.7% a year ago
down 8.9% from a year ago at actual exchange rates
down 9.8% from 79.40 a year ago
up 1.4 pp from 65.2% a year ago
up 1.5% from 151 a year ago
up 11.5% from a year ago at actual exchange rates
Where each number comes from
- Revenue (JPY billion): “Revenue | 1,106.7 | 1,219.9 | 113.2 | 10.2% | (0.5)% | 7,502 Cost of sales | (384.7) | (406.7)”
- Operating profit (JPY billion): “Operating profit | 184.6 | 201.4 | 16.9 | 9.1% | (3.1)% | 1,239 Margin | 16.7% | 16.5% | (0.2)”
- Operating margin: “Operating profit | 184.6 | 201.4 | 16.9 | 9.1% | (3.1)% | 1,239 Margin | 16.7% | 16.5% | (0.2)”
- Net profit attributable to owners (JPY billion): “Net profit (loss) attributable to owners of the Company | 124.2 | 113.2 | (11.0) | (8.9)% | (23.5)% | 696”
- Basic EPS (JPY): “Basic EPS (JPY or USD) | 79.40 | 71.65 | (7.76) | (9.8)% | (24.2)% | 0.44”
- Gross margin: “Gross profit | 722.0 | 813.2 | 91.2 | 12.6% | 1.7% | 5,001 Margin | 65.2% | 66.7% | 1.4 | pp | 1.4 | pp | 66.7%”
- Core EPS (JPY): “Basic EPS (JPY or USD) | 151 | 154 | 2 | 1.5% | (11.8)% | 0.95”
- Core operating profit (JPY billion): “Operating profit | 321.8 | 358.9 | 37.1 | 11.5% | (0.5)% | 2,207 Margin | 29.1% | 29.4% | 0.3”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue forecast (JPY billion) | FY2026 | 4,640.0 |
| Core operating profit forecast (JPY billion) | FY2026 | 1,160.0 |
| Core EPS forecast (JPY) | FY2026 | 472 |
| Adjusted free cash flow forecast (JPY billion) | FY2026 | 650.0 to 750.0 |
| Capital expenditures forecast (JPY billion) | FY2026 | 330.0 - 380.0 |
Key takeaways
Orexin agonist launch for NT1 is on track
Takeda says it is on track to bring the first and only orexin agonist to patients with narcolepsy type 1. A first-in-class product in a defined patient group gives the company a clear new growth driver.
Rusfertide gets FDA priority review, launching 2H 2026
Rusfertide has obtained U.S. FDA priority review, and Takeda expects a U.S. launch in the second half of 2026. Priority review shortens the path to market and brings a new product to the U.S. portfolio this year.
Another U.S. launch is planned for first-half 2027
Management said it is on track to launch a further product in the U.S. in the first half of 2027. Together with the 2026 launches, this builds a sequence of new products to replace revenue from products facing generics.
IBD brand keeps first-line lead despite lower sales
Takeda says sales of its leading IBD brand were down year over year at constant exchange rates, but overall demand is growing. It remains the #1 prescribed brand in IBD overall, with first-line leadership in ulcerative colitis (UC).
Indonesia plasma collaboration expands supply footprint
Takeda recently announced what it called a landmark collaboration with the Indonesian government to build plasma operations in the country. It extends the company's plasma-derived therapies business into a new market and supply base.
Questions
What are Takeda's main new product launches?
Takeda says it is on track to bring the first and only orexin agonist to patients with NT1. It also expects a U.S. launch of rusfertide in the second half of 2026, after the FDA granted priority review, and another U.S. launch in the first half of 2027.
How is Takeda's IBD franchise performing?
Sales of its leading IBD brand were down year over year at constant exchange rates, but management sees overall demand growth. It remains the #1 prescribed brand in IBD overall, with first-line leadership in UC.
What is hurting the portfolio?
Continued U.S. generic erosion of VYVANSE is a main headwind. Takeda's full-year forecast expects FX tailwinds and newly launched products to more than offset the impact of products losing exclusivity.
What is Takeda doing in plasma?
Takeda recently announced a landmark collaboration with the Indonesian government to build plasma operations in the country. It adds a new supply and market position to its plasma business.
What legal and partnership items affect Takeda's plans?
Management expects the AMITIZA antitrust litigation to take roughly 3 to 5 years. The FY2026 forecast also includes up to USD 400 million in payments to Protagonist Therapeutics tied to its opt-out from the 50/50 U.S. profit and loss share.
Documents
SEC filing